Clover Health Investments (CLOV) Pulls Back As The Medicare Advantage Narrative Still Points To Value

Simply Wall St · 1d ago

Clover Health Investments (CLOV) has drawn fresh attention after a recent pullback, with the share price closing at US$3.77 and short term returns under pressure, despite a stronger year to date performance.

Recent trading tells a mixed story for Clover Health Investments. The share price has fallen 9.6% in the past day and is down about 21% over both the past week and past month. However, the year-to-date share price return is 56.4% and the 1-year total shareholder return is 74.5%, which suggests that sentiment has cooled in the short run even as longer term holders remain well ahead on a total return basis.

Scan how Clover Health Investments compares with other rebound candidates by reviewing the curated 35 high quality undervalued stocks that pair stronger balance sheets with compressed valuations.

The sharp pullback in Clover Health Investments after a strong 1-year run raises a simple question. Are traders just resetting sentiment, or does the latest move better reflect the underlying Medicare Advantage business and software platform economics?

Most Popular Narrative: 31% Undervalued

Clover Health Investments closed at $3.77 compared with a narrative fair value of $5.50. The analyst consensus Narrative on Simply Wall St frames that gap around Medicare Advantage scale, cohort economics and the software platform.

Ongoing maturation of large recent Medicare Advantage cohorts, which management reports typically add around US$70 per member per month in insurance gross profit from year 1 to year 2 with further gains into year 3, creates a pipeline of members that can contribute more to gross profit, adjusted EBITDA and net income over time.

See why 47 investors see Clover Health Investments as 31% undervalued.

Result: Fair Value of $5.50 (UNDERVALUED)

Still, the narrative can break if outpatient utilization and related medical costs stay elevated, or if reserve swings and prior-period adjustments continue to distort reported profit.

Find out about the key risks to this Clover Health Investments narrative.

Another View: Cash Flows Paint A Different Picture

The first lens on Clover Health Investments leans on earnings and price targets that point to upside. A second lens using the Simply Wall St DCF model is more cautious. On that basis, the estimated future cash flow value sits at $3.40, which is below the current $3.77 share price and implies an overvalued signal on this method. It raises a simple question for investors: Which set of assumptions feels more realistic to you, the earnings path or the cash flow path?

For a closer look at how the cash flow math is built and where it might be conservative or optimistic, Look into how the SWS DCF model arrives at its fair value.

CLOV Discounted Cash Flow as at Nov 2026
CLOV Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Clover Health Investments for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment looks split around Clover Health Investments right now, so act quickly on the data and pressure test it against your own expectations using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Clover Health Investments?

If Clover Health Investments is on your radar, do not stop there. Broaden your watchlist now or risk missing opportunities sitting in plain sight.